term

Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee

- Pain Reductions Observed at Eight Weeks Sustained up to 12 Weeksand Drug Remains Very Well Tolerated - SOUTH SAN FRANCISCO, Calif., July 02, 2007/PRNewswire-FirstCall/ -- Anesiva, Inc. today announced preliminarylonger-term, follow-up results from a Phase 2 study showing that a1mg treatment with Adlea(TM) (formerly 4975) in patients withmoderate-to-severe osteoarthritis of the knee prod...

Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Children's Hospital and Stanford

STANFORD, Calif.--(BUSINESS WIRE)--Jun 29, 2007 - The drug mostcommonly used to arrest preterm labor, magnesium sulfate, is morelikely than another common treatment to cause mild to serious sideeffects in pregnant women, according to a study from researchers atLucile Packard Children's Hospital and Stanford University Schoolof Medicine. Their findings suggest that, since the effectivenessof...

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze byAlmost Half ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007/PRNewswire-FirstCall/ -- Abbott and MedImmune today announcedresults of a new study, published in the July issue of Journal ofPediatrics, showing that treatment with Synagis(R) (palivizumab)may reduce recurrent wheezing in premature infants by almosthalf.<...

Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells

SAN DIEGO--(BUSINESS WIRE)--Jun 27, 2007 - The University ofPittsburgh School of Health Sciences issued the following study andpress release, "Scientists Culture Blood-Forming Stem Cells fromHuman Fat Tissue," June 15, 2007, Science Daily: "Researchers atthe University of Pittsburgh School of Medicine have successfullyisolated and cultured human hematopoietic stem cells from fat, oradipose...

First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes

-- Additional Findings Reported on Glucose Homeostasis Effects inNormal and Diabetic Rats -- CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day,Phase IIa study of the safety profile of multiple doses of theinvestigational compound dapagliflozin, a selective inhibitor ofthe Sodium-Glucose Transporter 2 (SGLT2) administered alone orconcomitantly with metformin in subjects with Typ...

Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine

CHICAGO, IL, Jun 09, 2007 (MARKET WIRE via COMTEX News Network)-- Endo Pharmaceuticals Inc., a wholly owned subsidiary of EndoPharmaceuticals Holdings Inc. (NASDAQ: ENDP), has presented resultsfrom a Phase III randomized, double-blind, placebo-controlledclinical trial evaluating Frova (frovatriptan succinate) 2.5 mgtablets as a six-day preventative treatment in women withdifficult-to-tre...

Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection

Study Shows Safety and Pharmacokinetics Similar to IV Doses inPhase 3 CLL Trial BERKELEY HEIGHTS, N.J., June 06, 2007 /PRNewswire-FirstCall/ --Genta Incorporated announced the publication of preliminaryclinical results that show the Company's lead anti-cancer drug,Genasense(R) (oblimersen sodium) injection, can be safelyadministered by intermittent subcutaneous (SC) injection, as wellas...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

CHICAGO – June 2, 2007 – Long-term treatment withpegylated interferon alfa-2b in stage III melanoma had asignificant and sustained impact on relapse-free survival (RFS),according to the results of the largest adjuvant trial everconducted in patients with stage III melanoma. Results of the PhaseIII study, led by...

8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar

Positive Results in Patients With Follicular Lymphoma ReportedToday at ASCO Annual Meeting PHILADELPHIA, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline plcannounced today long-term efficacy data from a Phase II trial of asingle one-week course of frontline treatment with the BEXXAR(R)Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in76 patients with newly diagnosed advanced...

Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics

WARRINGTON, Pa., May 31, 2007 (PRIME NEWSWIRE) -- DiscoveryLaboratories, Inc. (Nasdaq:DSCO) announces publication of theone-year follow-up results from its SELECT and STAR Phase 3clinical trials for Surfaxin(r), in Pediatrics, the premier medicaljournal for pediatric healthcare practitioners. The long-term datafrom the SELECT and STAR trials concluded that Surfaxindemonstrated a statisti...

PARI and Kamada Announce Positive Intermediate Phase I Results for Inhaled Alpha-1 Antitrypsin

MONTEREY, Calif., May 31, 2007 /PRNewswire-FirstCall/ -- Thefirst of two stages of the Phase I clinical trial show positiveresults for Kamada's Alpha-1 Antitrypsin (AAT) liquid drugcandidate for inhalation delivered with PARI's eFlow electronicnebulizer for the treatment of patients suffering from AATdeficiency. Dosage levels studied resulted in good safety profilesand patient tolerabili...

Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates

SEATTLE, May 31, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a measles DNA vaccine formulatedwith the company's Vaxfectin(TM) adjuvant elicited protectivelevels of neutralizing antibodies in juvenile (1 - 2 year old)nonhuman primates confirmed by complete protection followingchallenge more than one year after vaccination, and sterilizingimmunity as evidenced by...

Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up

Separate Survey Underscores Impact of Disease on Work Status andProductivity WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ -- Findingspresented today at Digestive Disease Week(R) 2007 (DDW), fromlong-term extensions of the ACT trials (Active Ulcerative Colitis 1& 2) show that subjects with moderately to severely activeulcerative colitis (UC) who had responded to REMICADE(R)(inflixi...

New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia

Six-Month Data Show Bifeprunox Maintained StabilitySignificantly Longer than Placebo and had a Favorable Weight andLipid Profile Comparable with Placebo MARIETTA, Ga. and COLLEGEVILLE, Pa., May 22, 2007 - SolvayPharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth(NYSE:WYE), and Lundbeck A/S presented clinical study results onbifeprunox, an investigational treatment for...

Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Medtronic(NYSE:MDT) today presented new long-term data from the ENDEAVORclinical trial program reinforcing the existing safety and efficacyprofile of the Endeavor(R) drug-eluting coronary stent system.Four-year results from the 100-patient first-in-man ENDEAVOR Itrial and three-year results from the nearly 1,200 patient ENDEAVORII trial demo...

Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years inhigh-risk patient population NATICK, Mass., and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced four-year follow-up data from its TAXUS VI clinicaltrial. The data demonstrated that the safety and efficacy benefitsassociated with a moderate-release formulation of the TAXUS(R)...

UCB Presents Long-Term CImzia Data in Crohn's Disease

Cimzia Maintained Long-term Response at Stable Doses, According toNew Data Presented at Digestive Disease Week (DDW) ATLANTA, May 22, 2007 /PRNewswire/ -- UCB announced today thatnew data presented at Digestive Disease Week 2007 (DDW)demonstrated long-term response and remission in Crohn's diseasepatients treated with Cimzia (certolizumab pegol), the only Fc-freePEGylated, Fab' fragment a...

PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week

Nuvion Antibody Led to a Sustained Response and Remission inFollow-up to Phase 1 and Phase 1/2 studies and Was AdequatelyTolerated in Patients with IV Steroid-Refractory Ulcerative Colitis FREMONT, Calif., May 22, 2007 /PRNewswire-FirstCall/ -- Datapresented at the Digestive Disease Week (DDW) meeting this week inWashington D.C. by Dr. William Sandborn from the Mayo Clinicsuggest that Nuv...

New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder

- Data Presented at 2007 APA Meeting - COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ -- Datafrom four new studies examining safety and efficacy ofdesvenlafaxine succinate, a serotonin-norepinephrine reuptakeinhibitor (SNRI) being studied as a potential treatment for adultswith major depressive disorder (MDD), were presented today at the2007 American Psychiatric Association annual...

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients takingonce-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- Along-term phase III, open-label 12-14 month extension study (303)presented at the British Society of Gastroenterology (BSG) meetingin Glasgow, Scotland in March 2007 showed Shire plc'sLialda(mesalamine) is w...

Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension

SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Gilead Sciences,Inc. (Nasdaq:GILD) today announced results of two long-term studiesevaluating ambrisentan, an investigational endothelin receptorantagonist (ERA) for the treatment of patients with pulmonaryarterial hypertension (PAH). These long-term data are from patientswho originally participated in the two pivotal Phase III ARIESstudies and...

Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer

ANAHEIM, Calif.--(BUSINESS WIRE)--May 21, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced additional follow-up data on thecompany's Phase 3 investigational therapeutic cancer vaccineOncophage(R) (vitespen). The end-of-study results, which reflect anadditional 17 months' data collection, showed that in a substantialsubset of patients (n = 362) at intermediate risk for diseaserecurrence,...

CEL-SCI Presents Long-Term Cancer Survival Data With Multikine

Multikine Improves Overall Survival by 33% 3.5 Years Post Surgery VIENNA, Va., May 21, 2007 /PRNewswire-FirstCall/ -- CEL-SCICORPORATION announced today that its cancer drug Multikine(R) wasshown to significantly increase long term overall survival in aPhase II study of head and neck cancer patients. The data werepresented on May 20, 2007 at the First International Congress ofthe Internat...

Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy

Data Also Show Nebivolol Lowers Blood Pressure in Obese andNon-Obese Hypertensive Patients CHICAGO, May 21, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. today presented positive data from two clinicalstudies and one pooled analysis of nebivolol, a selective beta1-blocker with vasodilating properties currently under review bythe U.S. Food and Drug Administration (FDA) for the tr...

InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting

Reports 'Picomolar' Potency and Slow Dissociation from HCVProtease WASHINGTON, May 21, 2007 /PRNewswire-FirstCall via COMTEX NewsNetwork/ -- InterMune, Inc. (Nasdaq: ITMN) today presented newpreclinical data on the company's Hepatitis C virus (HCV) NS3/4Aprotease inhibitor, ITMN-191, during a scientific session of theDigestive Disease Week (DDW) meeting being held May 19-24 inW...

Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies

-- Large multi-year, multi-hospital retrospective database analysisdemonstrates RDS treatment with Curosurf(R) (poractant alfa)Intratracheal Suspension provides significantly improved neonatalsurvival -- NAPA, Calif. and PARMA, Italy, May 07, 2007 /PRNewswire/ -- Datapresented today at the Pediatric Academic Societies' Annual Meetingdemonstrate that premature infants with neonatal Respira...

Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntington's Disease

BOSTON--(BUSINESS WIRE)--May 3, 2007 - New data show theinvestigational drug tetrabenazine maintained reduction of choreaassociated with Huntington's disease (HD) up to 80 weeks in thosepatients who successfully completed treatment in a 13-week trial.These data suggest that tetrabenazine can be used successfully tosustain reduced chorea burden in long-term use. "These findings demonstrate...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data havedemonstrated that relapsing-remitting multiple sclerosis (RRMS)patients treated with COPAXONE(R) (glatiramer acetate injection)following brief immunosuppression with mitoxantrone experienced a90 percent reduction in magnetic resonance imaging (MRI)-monitoreddisease activity compared to their baseline. These benefits wereachieved...

Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron

BOSTON, May 03, 2007 /PRNewswire/ -- Bayer HealthCarePharmaceuticals announced today the results of three clinicalstudies with Betaseron(R) (interferon beta-1b), presented this weekat the American Academy of Neurology's (AAN) 59th Annual Meeting,demonstrating early efficacy, long-term tolerability, and highpatient satisfaction with treatment in patients with relapsingforms of multiple sc...

Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 1, 2007 - AvanirPharmaceuticals (NASDAQ:AVNR) today announced that data on thelong-term safety of the investigational drug Zenvia(TM)(dextromethorphan / quinidine) and the prevalence of InvoluntaryEmotional Expression Disorder (IEED) were presented today during aposter session at the American Academy of Neurology (AAN) 59thAnnual Meeting in Boston....

Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria

The research, done in collaboration with the Centro deInvestigación Médica Aplicada (CIMA) at theUniversity of Navarra, Pamplona, Spain, is being presented atPorphyrins and Porphyrias Congress, Rotterdam, the Netherlands. AMSTERDAM, the Netherlands, May 1st 2007 - Amsterdam MolecularTherapeutics BV (AMT), a leader in the field of human gene therapy,will today present...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

LIVINGSTON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced that preliminaryresults from the ongoing data analysis of the recently-completedrandomized, placebo-controlled, double-blind Phase III clinicaltrial of PROCHIEVE(R) 8% (progesterone gel) for the prevention ofpreterm birth in women with a previous preterm birth earlier than35 weeks ges...

Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients

Encouraging Results Prompted Phase 2 Study Now Underway at NineCenters SAN DIEGO, Calif., April 16, 2007 /PRNewswire/ -- Ceregene,Inc., a biopharmaceutical company, today presented long termfollow-up data from a Phase 1 clinical trial of CERE-120, a genetherapy product in development for the treatment of Parkinson'sdisease, demonstrating a 36 percent (p<0.001) reduction inParkinson's sym...

First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

KANSAS CITY, Mo.--(BUSINESS WIRE)--Apr 11, 2007 - A comparison ofthe long-term economic outcomes of four immunomodulatory drugtherapies combined with symptom management versus symptommanagement alone revealed that COPAXONE(R) (glatiramer acetateinjection) was the most cost-effective treatment strategy forrelapsing-remitting multiple sclerosis (RRMS). The study providesthe first pharmacoecon...

InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting

Presentations include preclinical data for potential combinationtherapies and details of N3/4A protease sequence variations afterITMN-191 exposure BARCELONA, Spain, April 11, 2007 /PRNewswire-FirstCall/ --InterMune, Inc. announced today the presentation of findings fromthree in vitro experiments concerning its HCV protease inhibitorITMN-191, alone or in combination with other compounds, a...

Icagen Terminates Phase III ASSERT Study

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 -Icagen, Inc. (NASDAQ: ICGN) announced today that following aplanned meeting of the independent Data Monitoring Committee("DMC") of the Company's ASSERT trial of senicapoc (formerlyICA-17043) for the treatment of sickle cell disease in adults, theDMC recommended that the trial be terminated because of the lowprobability of achieving...

ACC Presentation Indicates Interleukin-1 Gene Variants Determine Increased Risk for Coronary Artery Disease from Oxidized Phospholipids

WALTHAM, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - InterleukinGenetics, Inc. (AMEX:ILI) and collaborators at the University ofCalifornia San Diego today reported at the American College ofCardiology annual meeting that associations between coronary arterydisease (CAD) and both oxidized phospholipids (OxPL) and Lp(a)levels appear to be dependent on pro-inflammatory variants of theinterleukin-1...

Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease

NEW ORLEANS, March 26, 2007 /PRNewswire-FirstCall/ -- Three-yearfollow-up data presented today at the of Cardiology's 56th AnnualScientific Session (ACC.07) showed that the CYPHER(R)Sirolimus-eluting Coronary Stent had results comparable to coronaryartery bypass grafting (CABG or bypass surgery) in patients withblockages in two or more vessels, one of the most complex patientpopulations...

Everest Data on Short- and Long-Term Use of Otsuka's Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC's Late Breaking Clinical Trials

PRINCETON, N.J., March 25, 2007 /PRNewswire/ -- Once-dailydosing with Otsuka's investigational oral medication tolvaptan, avasopressin receptor antagonist, was associated with improvementsin signs and symptoms of acutely decompensated heart failure (ADHF)in hospitalized patients receiving conventional care, without anadverse effect on their long-term survival versus placebo.(1) Thesedata...

Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - NymoxPharmaceutical Corporation (NASDAQ: NYMX) today announced positiveresults from its newly completed long-term outcome study of NX-1207for benign prostatic hyperplasia (BPH). 26 clinical trial sitesacross the U.S. and 116 unselected subjects participated in theblinded, placebo controlled study. The study assessed symptom scores a...